← Product Code FRO · K082089 # PRUMYX CREAM (K082089) _Prugen, Inc. · FRO · Jan 13, 2009 · SU · SESE_ **Canonical URL:** https://fda.innolitics.com/device/K082089 ## Device Facts - **Applicant:** Prugen, Inc. - **Product Code:** FRO - **Decision Date:** Jan 13, 2009 - **Decision:** SESE - **Submission Type:** Traditional - **Device Class:** Class U - **Review Panel:** SU - **Attributes:** Therapeutic ## Intended Use The prescription form of PruMyx™ Cream requires a physician diagnosis of a disease state and is indicated for the management and relief of the burning and itching experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis. The OTC version of the device helps to relieve dry, waxy skin by maintaining a moist wound & skin environment, which is beneficial to the healing process. ## Device Story PruMyx™ Cream is a non-sterile, semi-viscous emulsion for topical application. Used in clinical or home settings; applied by patients or healthcare providers to affected skin areas three times daily or as needed. Acts as a topical dressing to maintain a moist wound and skin environment; relieves burning, itching, and dry skin associated with dermatoses or minor burns. Benefits include support of the natural healing process through moisture maintenance. No complex processing or electronic components involved. ## Clinical Evidence Bench testing only. Functional and performance testing conducted to assess safety and efficacy; results reported as satisfactory. ## Technological Characteristics Non-sterile, semi-viscous emulsion. Topical delivery. No electronic components, software, or specific material standards cited. ## Predicate Devices - MimyX® Cream ([K041342](/device/K041342.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ **PRUGEN, INC.** K082-089/5, ## Revised 510(k) Summary ## Date Prepared: January 9, 2009. JAN 1 3 2009 | 1. | Owner's Name: | PruGen, Inc.
8711 East Pinnacle Peak Road
Suite C-201
PMB 225
Scottsdale, AZ 85255 | |----|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | Contact Person: | Robert L. Knechtel
PruGen, Inc.
8711 East Pinnacle Peak Road
Suite C-201, PMB 225
Scottsdale, AZ 85255
(T): 602-300-2378
(F): 815-261-5953
(E): rknechtel@prugen.com | | 2. | Proprietary Name: | PruMyx™ Cream | | | Common Name: | Dressing, Wound & Burn, Hydrogel w/ Drug or Biologic | | | Classification Name: | Dressing, Wound & Burn, Hydrogel w/ Drug or Biologic
(Product Code FRO) | #### Substantially Equivalent Devices: 3. PruGen, Inc. believes that PruMyx™ Cream is substantially equivalent to the following currently marketed device: MimyX® Cream cleared under K041342. #### Device Description: 4. PruMyx™ Cream is a non-sterile, semi-viscous emulsion intended for topical application. It is presented for both Prescription (requiring a physician diagnosis disease state) and over-the-counter (OTC) use. #### Intended Use of the Device: ડાં The prescription form of PruMyx™ Cream requires a physician diagnosis of a disease state and is indicated for the management and relief of the burning and itching experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis. The OTC dermatoses, niciding dopted with the enrely symptoms such as burning and itching associated with many velsion of the device is minibator of genere belps to relieve dry, waxy skin by maintaining a moist wound & skin environment, which is beneficial to the healing process. ### Summary of Technical Characteristics of Device compared to Predicate Devices 6. All referenced predicate devices are non-sterile emulsions that are applied to relieve the symptoms of various dermatoses. #### 7. Conclusions: Functional and performance testing has been conducted to assess the safety and efficacy PruMyx™ Cream and results are satisfactory. 8711 East Pinnacle Peak Road · Suite C-201, PMB 225 · Scottsdale, AZ 85255 · 480.585.0122 {1}------------------------------------------------ ## DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with three bars above it, representing the department's commitment to health, human services, and well-being. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle symbol. ### Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 # JAN 1 3 2009 PruGen, Inc. % Robert L. Knechtel, M.D., J.D. 10 South LaSalle Street, Suite 3300 Chicago, Illinois 60603 Re: K082089 Trade/Device Name: PruMyx™ Cream Regulatory Class: Unclassified Product Code: FRO Dated: October 7, 2008 Received: October 14, 2008 Dear Dr. Knechtel: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register, Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally ... {2}------------------------------------------------ ## Page 2 - Robert L. Knechtel, M.D., J.D. marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket, Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events. (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours. Mark N. Millerson Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {3}------------------------------------------------ ## INDICATIONS FOR USE 510(k) number (if known): K082089 Device Name: PruMyx™M Cream Indications for Use: ## FOR TOPICAL DERMATOLOGICAL USE ONLY ## Description Rx Product: Under the supervision of a healthcare professional, PruMyx Cream is indicated to manage and relieve the burning and itching experienced with various-types of dermatoses, including radiation dermatitis, atopic dermatitis and allergic contact dermatitis. PruMyx Cream helps to relieve dry waxy skin by maintaining a moist wound & skin environment, which is beneficial to the healing process. ## Directions for Use (Rx and OTC): Apply PruMyx Cream to the affected skin areas 3 times per day (or as needed), and massage gently into the skin. If the skin is broken, cover PruMyx Cream with a dressing of choice. ### Description OTC Product: PruMyx Cream helps to nourish skin and relieve the burning and itching associated with many common types of skin irritation. PruMyx Cream may also be used to soothe minor bums, including sunburn. Prescription Use \ (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use ☑ (Part 21 CFR 801 Subpart C) 108 2089 KI 111 (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of General, Restorative, and Neurological Devices 510(k) Number C612085 Page 1 of 1 (Posted November 13, 2003). --- **Source:** [https://fda.innolitics.com/device/K082089](https://fda.innolitics.com/device/K082089) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com